‹ Back to Physician Directory

Jaime Hatcher-Martin


Movement Disorders Director

Request Appointment

About the doctor


Undergrad - University of South Florida (BS Biology, minor Gerontology)

Med school - Emory University School of Medicine (MD/PhD)


Emory University School of Medicine (Neurology)


Emory University School of Medicine (Movement Disorders)


2015-2019: American Academy of Neurology Telemedicine Working Group (Co-Chair) 

2017-current: International Parkinson’s Disease and Movement Disorders Society Telemedicine Work Group 

2017-2020: American Academy of Neurology Innovation Hub Working Group 

2019-current: Huntington Study Group (HSG) Family Day Planning Committee 

2020: American Academy of Neurology Emergency Telemedicine Work Group 

2020: American Academy of Neurology Telemedicine Reimbursement Work Group 

2019-2021: American Academy of Neurology Practice Management and Technology Subcommittee  

2019-2021: Cerner Neurology Physician Advisor Council 

2020-2021: American Academy of Neurology Teleneurology Education Curriculum for Residents Workgroup 

2020-2021: American Academy of Neurology Innovation in Practice Work Group 

2020-2021: Children Neurology Foundation Telehealth Initiative 

2021-current: American Academy of Neurology Medical Economics and Practice (MEP) Telehealth Subcommittee 

2023-current: Huntington Study Group (HSG) Credentialing Committee

2023-current: Huntington Study Group (HSG) Education Committee


I grew up just outside of Tampa and am now living in the Atlanta suburbs with my husband, two sons and our goofball Frenchie. I’ve never lost my Florida roots though—the closer to the ocean the better! I love to read, travel and exercise (weight training) and I’m learning to golf.

I’ve been interested in neuroscience since high school having actually attended a summer program in Virginia. I was attracted to neuroscience/neurology because of my fascination with what makes us truly human. In undergrad, I worked in a research lab focused on Alzheimer’s disease but ultimately focused on movement disorders for both my PhD dissertation work as well as my MD and residency. It was the hands-on component of movement disorders that I loved! Ironic, now that I’m focused on telemedicine but time and again, I encountered patients who had trouble getting to appointments either because they were too busy living their lives to slow down for their disease, had been affected enough that travel ws difficult or just lived too far away to make repeated trips.

This led to me creating the first telehealth neurology clinic for patients in rural Georgia in 2016—focused on movement disorders. I found that even without the hands on, I have been able to establish great relationships with my patients though I do miss the hugs! I have participated in various telehealth committees at the national and international level—focusing on ways to improve access to care. Now, I have the privilege to surround myself with a team that shares my passion and vision for what healthcare can be. I am honored to get to know my patients and their families and hopefully provide some light in their journey.

Fun fact

I almost died at birth due to lack of oxygen (anoxia). Once they were sure I was going to survive, the doctors told my Mom it could be years before they knew if I had any permanent brain damage!


Hatcher-Martin JM, McKay J, Sommerfeld B, Howell J, Goldstein F, Factor SA. “Cerebrospinal fluid biomarkers in Parkinson's disease with freezing of gait: an exploratory analysis.” 2021. NPJ Parkinsons Dis. 29(7): 105.

Hatcher-Martin JM, Anderson EA, Busis NA, Bove RM, Cohen BH, Fritz JV, Jones EC, Shook SJ, Wolf RA. AAN Telehealth Position Statement. 2021. Neurology. 98(7): 334-339.

Cubo E, Hassan A, Bloem BR, Mari Z…Hatcher-Martin JM… on behalf of the International Parkinson and Movement Disorder Society (MDS) Telemedicine Work Group. 2020. Implementation of Telemedicine for Urgent and Ongoing Healthcare for Patients with Parkinson’s Disease During the COVID-19 Pandemic: New Expectations for the Future. J Parkinsons Dis. 10(3):911-913.

Hatcher-Martin JM, Adams JL, Anderson ER, Bove R, Burrus TM, Chehrenama M, Dolan O'Brien M, Eliashiv DS, Erten-Lyons D, Giesser BS, Moo LR, Narayanaswami P, Rossi MA, Soni M, Tariq N, Tsao JW, Vargas BB, Vota SA, Wessels SR, Planalp H, Govindarajan R. 2020. Telemedicine in neurology: Telemedicine Work Group of the American Academy of Neurology Update. Neurology. 94(1):30-38.

Hu WT, Howell JC, Ozturk T, Gangishetti U, Kollhoff AL, Hatcher-Martin JM, Anderson AM, Tyor WR. 2019. Front Immunol. 10:480.

Ben-Pazi H, Browne P, Chan P, Cubo E, Guttman M, Hassan A, Hatcher-Martin JM, Mari Z, Moukheiber E, Okubadejo NU, Shalash A, and the International Parkinson and Movement Disorder Society Telemedicine Task Force. 2018. The Promise of Telemedicine for Movement Disorders: An Interdisciplinary Approach. Invited article for Movement Disorders. Curr Neurol Neurosci Rep. 18(5):26.

Hatcher-Martin JM, Armstrong KA, Scorr LM, Factor SA. 2016. Propranolol therapy for Tardive Dyskinesia: A retrospective examination. Parkinsonism Relat Disord. 32:124-126.

Hatcher-Martin JM and Factor SA. 2016. Freezing of Gait: A Rare Delayed Complication of Whole Brain Radiation. Parkinsonism Relat Disord. 29:129-130.

Factor SA, Hatcher-Martin JM, Morse AS, Nocera JR, Revuelta FJ. 2016. Freezing of gait that disappears: Should there be rest before Rehab? Parkinsonism Relat Disord. 28:169-170.

Hatcher-Martin JM, Shaikh AG, Factor SA. 2015. Chapter 22: Stereotypies in Parkinson’s Disease and Movement Disorders. Jankovic J and Tolosa E (eds). Wolters Kluwer. pp 233-39.

Hatcher-Martin JM, Gearing M, Steenland K, Levey AI, Miller GW, Pennell KD. 2012. Association between polychlorinated biphenyls and Parkinson's disease neuropathology. Neurotoxicology. 33 (5): 1298-1304.

Hatcher JM, Delea KC, Richardson JR, Pennell KD, Miller GW. 2008. Disruption of dopamine transport by DDT and its metabolites. Neurotoxicology. 29 (4): 682-690.

Hatcher JM, Pennell KD, Miller GW. 2008. Parkinson’s diseases and pesticides: a toxicological perspective. Trends Pharmacol Sci. 29 (6): 322-329.

Hatcher JM, Miller GW, Jones DP, Pennell KD. 2008. Chapter 16: Neurotoxicity of manufactured nanoparticles, in Nanoscience and Nanotechnology: Environmental and Health Impact. Grassian, VH (ed). John Wiley & Sons; 405-428.

Hatcher JM, Richardson JR, Guillot TS, McCormack AL, Di Monte DA, Jones DP, Gearing M, Levey AI, Pennell KD, Miller GW. 2007. Elevated levels of the pesticide dieldrin are associated with Parkinson’s disease. Experimental Neurology. 204 (2): 619-630.

Arendash GW. King DL. Gordon MN. Morgan D. Hatcher JM. Hope CE. Diamond DM. 2001. Progressive, age-related behavioral impairments in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenes. Brain Research. 891(1-2):42-53.

Arendash GW. Gordon MN. Diamond DM. Austin LA. Hatcher JM. Jantzen P. DiCarlo G. Wilcock D. Morgan D. 2001. Behavioral assessment of Alzheimer's transgenic mice following long-term A-beta vaccination: task specificity and correlations between A-beta deposition and spatial memory. DNA & Cell Biology. 20(11):737-44.

Gordon MN. King DL. Diamond DM. Jantzen PT. Boyett KV. Hope CE. Hatcher JM, DiCarlo G. Gottschall WP. Morgan D. Arendash GW. 2001. Correlation between cognitive deficits and A beta deposits in transgenic APP+PS1 mice. Neurobiology of Aging. 22(3):377-85.

Morgan D. Diamond DM. Gottschall PE. Ugen KE. Dickey C. Hardy J. Duff K. Jantzen P. DiCarlo G. Wilcock D. Connor K. Hatcher J. Hope C. Gordon M. Arendash GW. 2000. A-beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 408(6815):982-5.

states licensed in

South Carolina
West Virginia
New York
Washington DC
South Dakota


No items found.